(A-US-52030-328) A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Auto/Gel Depot 120 mg Plus BSC Vs. Placebo Plus BSC for Tumor Control in Subjects with Well Differentiated, Metastatic And/Or Unresectable Typical or Atyplcal Lung Neuroendocrine Tumors
Description: 

To compare the antitumour efficacy of LAN plus BSC every 28 days monotherapy versus placebo plus BSC, in terms of progression free survival (PFS), measured by central review using Response Evaulation Criteria in Solid Tumours (RECIST) v1.1 criteria, every 12 weeks, in subjects with unresectable and/or metastatic well differentiated, typical or atypical lung neuroendocrine tumours.

Study Number: 

PH 281716

Phase: 
3
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02683941

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.